tetano
Editor, Senior Moderator
J Clin Med
. 2021 May 13;10(10):2099.
doi: 10.3390/jcm10102099.
Accuracy of a Novel SARS-CoV-2 Antigen-Detecting Rapid Diagnostic Test from Standardized Self-Collected Anterior Nasal Swabs
Bilgin Osmanodja[SUP] 1 [/SUP], Klemens Budde[SUP] 1 [/SUP], Daniel Zickler[SUP] 1 [/SUP], Marcel G Naik[SUP] 1 2 [/SUP], Jörg Hofmann[SUP] 3 4 [/SUP], Maximilian Gertler[SUP] 5 [/SUP], Claudia Hülso[SUP] 5 [/SUP], Heike Rössig[SUP] 6 [/SUP], Philipp Horn[SUP] 6 [/SUP], Joachim Seybold[SUP] 6 [/SUP], Stephanie Lunow[SUP] 5 [/SUP], Melanie Bothmann[SUP] 5 [/SUP], Astrid Barrera-Pesek[SUP] 5 [/SUP], Manuel Mayrdorfer[SUP] 1 [/SUP]
Affiliations
Abstract
Background Antigen-detecting rapid diagnostic tests (Ag-RDT) for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) offer new opportunities for the quick and laboratory-independent identification of infected individuals for control of the SARS-CoV-2 pandemic. Despite the potential benefits, nasopharyngeal sample collection is frequently perceived as uncomfortable by patients and requires trained healthcare personnel with protective equipment. Therefore, anterior nasal self-sampling is increasingly recognized as a valuable alternative. Methods We performed a prospective, single-center, point of care validation of an Ag-RDT using a polypropylene absorbent collector for standardized self-collected anterior nasal swabs. Real-time polymerase chain reaction (RT-PCR) from combined oropharyngeal/nasopharyngeal swabs served as a comparator. Primary endpoint was sensitivity of the standardized Ag-RDT in symptomatic patients with medium or high viral concentration (≥1 million RNA copies on RT-PCR for SARS-CoV-2). Results Between 12 February and 22 March 2021, 388 participants were enrolled. After exclusion of 9 patients for which no PCR result could be obtained, the novel Ag-RDT was evaluated based on 379 participants, of whom 273 were symptomatic and 106 asymptomatic. In 61 samples from symptomatic patients with medium or high viral load (≥1 million RNA copies), the sensitivity of the standardized Ag-RDT was 96.7% (59/61; 95% confidence interval (CI): 88.7-99.6%) for the primary endpoint. In total, 62 positive Ag-RDT results were detected out of 70 RT-PCR positive individuals, yielding an overall sensitivity of 88.6% (95% CI: 78.7-94.9%). Specificity was 99.7% (95% CI: 98.2-100%) in 309 RT-PCR negative individuals. Conclusions Here, we present a validation of a novel Ag-RDT with a standardized sampling process for anterior nasal self-collection, which meets World Health Organisation (WHO) criteria of ≥80% sensitivity and ≥97% specificity. Although less sensitive than RT-PCR, this assay could be beneficial due to its rapid results, ease of use, and suitability for standardized self-testing.
Keywords: COVID-19; COVID-19 diagnostic testing; SARS-COV-2 antigen testing; SARS-CoV-2.
. 2021 May 13;10(10):2099.
doi: 10.3390/jcm10102099.
Accuracy of a Novel SARS-CoV-2 Antigen-Detecting Rapid Diagnostic Test from Standardized Self-Collected Anterior Nasal Swabs
Bilgin Osmanodja[SUP] 1 [/SUP], Klemens Budde[SUP] 1 [/SUP], Daniel Zickler[SUP] 1 [/SUP], Marcel G Naik[SUP] 1 2 [/SUP], Jörg Hofmann[SUP] 3 4 [/SUP], Maximilian Gertler[SUP] 5 [/SUP], Claudia Hülso[SUP] 5 [/SUP], Heike Rössig[SUP] 6 [/SUP], Philipp Horn[SUP] 6 [/SUP], Joachim Seybold[SUP] 6 [/SUP], Stephanie Lunow[SUP] 5 [/SUP], Melanie Bothmann[SUP] 5 [/SUP], Astrid Barrera-Pesek[SUP] 5 [/SUP], Manuel Mayrdorfer[SUP] 1 [/SUP]
Affiliations
- PMID: 34068236
- DOI: 10.3390/jcm10102099
Abstract
Background Antigen-detecting rapid diagnostic tests (Ag-RDT) for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) offer new opportunities for the quick and laboratory-independent identification of infected individuals for control of the SARS-CoV-2 pandemic. Despite the potential benefits, nasopharyngeal sample collection is frequently perceived as uncomfortable by patients and requires trained healthcare personnel with protective equipment. Therefore, anterior nasal self-sampling is increasingly recognized as a valuable alternative. Methods We performed a prospective, single-center, point of care validation of an Ag-RDT using a polypropylene absorbent collector for standardized self-collected anterior nasal swabs. Real-time polymerase chain reaction (RT-PCR) from combined oropharyngeal/nasopharyngeal swabs served as a comparator. Primary endpoint was sensitivity of the standardized Ag-RDT in symptomatic patients with medium or high viral concentration (≥1 million RNA copies on RT-PCR for SARS-CoV-2). Results Between 12 February and 22 March 2021, 388 participants were enrolled. After exclusion of 9 patients for which no PCR result could be obtained, the novel Ag-RDT was evaluated based on 379 participants, of whom 273 were symptomatic and 106 asymptomatic. In 61 samples from symptomatic patients with medium or high viral load (≥1 million RNA copies), the sensitivity of the standardized Ag-RDT was 96.7% (59/61; 95% confidence interval (CI): 88.7-99.6%) for the primary endpoint. In total, 62 positive Ag-RDT results were detected out of 70 RT-PCR positive individuals, yielding an overall sensitivity of 88.6% (95% CI: 78.7-94.9%). Specificity was 99.7% (95% CI: 98.2-100%) in 309 RT-PCR negative individuals. Conclusions Here, we present a validation of a novel Ag-RDT with a standardized sampling process for anterior nasal self-collection, which meets World Health Organisation (WHO) criteria of ≥80% sensitivity and ≥97% specificity. Although less sensitive than RT-PCR, this assay could be beneficial due to its rapid results, ease of use, and suitability for standardized self-testing.
Keywords: COVID-19; COVID-19 diagnostic testing; SARS-COV-2 antigen testing; SARS-CoV-2.